reports
Novo Nordisk phase 2 trial with amycretin reports significant weight l...
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeksAmycretin demonstrated statistically significant reductions in HbA1c with up to 89.1% achieving HbA1c levels below 7%Amycretin appeared to have a safe and well-tolerated profile consistent with incretin and amylin-based therapies Bagsværd, Denmark, 25 November 2025 – Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. Th...
- Delphine Brault
- Jean-François Granjon
- Marc Lavaud
- Nathan Mietlicki
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
G1A GEA GROUP AG
ABB ABB LTD.
RXL REXEL SA
CPG COMPASS GROUP PLC
OERL OC OERLIKON CORPORATION AG
ALO ALSTOM SA
SCHP SCHINDLER HOLDING AG PREF
NEX NEXANS SA
EZJ EASYJET PLC
SUN SULZER AG
KRN KRONES AG
DOKA DORMAKABA HOLDING AG
KGX KION GROUP AG
ASSA B ASSA ABLOY AB CLASS B
BCHN BURCKHARDT COMPRESSION HOLDING AG
PRY PRYSMIAN S.P.A.
ANDR ANDRITZ AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
JUN3 JUNGHEINRICH AG PREF
SIE SIEMENS AG
NKT NKT A/S
DUE DURR AG
VOS VOSSLOH AG
SANT S&T AG
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
KBX KNORR-BREMSE AG
PRX PROSUS N.V. CLASS N
SRAIL STADLER RAIL AG
ENR SIEMENS ENERGY AG
ATCO A ATLAS COPCO AB
STMN STRAUMANN HOLDING AG
ACLN ACCELLERON INDUSTRIES LTD
NOVO B NOVO NORDISK A/S
AGN AEGON N.V.
PFSE PFISTERER HOLDING SE
- Delphine Brault
- Jean-François Granjon
- Marc Lavaud
- Nathan Mietlicki
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
G1A GEA GROUP AG
ABB ABB LTD.
RXL REXEL SA
CPG COMPASS GROUP PLC
OERL OC OERLIKON CORPORATION AG
ALO ALSTOM SA
SCHP SCHINDLER HOLDING AG PREF
NEX NEXANS SA
EZJ EASYJET PLC
SUN SULZER AG
KRN KRONES AG
DOKA DORMAKABA HOLDING AG
KGX KION GROUP AG
ASSA B ASSA ABLOY AB CLASS B
BCHN BURCKHARDT COMPRESSION HOLDING AG
PRY PRYSMIAN S.P.A.
ANDR ANDRITZ AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
JUN3 JUNGHEINRICH AG PREF
SIE SIEMENS AG
NKT NKT A/S
DUE DURR AG
VOS VOSSLOH AG
SANT S&T AG
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
KBX KNORR-BREMSE AG
PRX PROSUS N.V. CLASS N
SRAIL STADLER RAIL AG
ENR SIEMENS ENERGY AG
ATCO A ATLAS COPCO AB
STMN STRAUMANN HOLDING AG
ACLN ACCELLERON INDUSTRIES LTD
NOVO B NOVO NORDISK A/S
AGN AEGON N.V.
PFSE PFISTERER HOLDING SE
- Martial Descoutures
- Martial Descoutures
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistic...
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care. The decision to pursue an Alzheimer’s disease indication with semaglutide w...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of ...
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 14 November 2025 - Today, Novo Nordisk A/S held its Extraordinary General Meeting, which was convened to elect new members of the Board of Directors. At the Extraordinary General Meeting, Helge Lund (chair), Henrik Poulsen (vice chair) and the Board members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay stepped down from the Board of Directors. Resolutions adopted at the Extraordinary General MeetingElections Election of Lars Rebien Sørensen as chair of the Board o...
Novo Nordisk A/S: Candidate for the Board of Directors will not seek e...
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise announced in the notice convening the Extraordinary General Meeting. Earlier today, Mikael Dolsten, who most recently served as the Head of R&D at Pfizer, informed Novo Nordisk that, in spite of his desire to join, he has decided to withdraw his candidacy to the Novo Nordisk Board of Directors, both as a m...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 11 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of ...
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
Novo Nordisk will not increase its proposal to acquire Metsera, Inc. Bagsværd, Denmark, 8 November 2025 – Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera. On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera) which was declared superior by Metsera’s board of directors. On 4 November 2025, Novo Nordisk confirmed that it had submitted an updated unsolicited proposal to acquire Metsera price of 62.20 USD per share in cash (equal to an approximate aggregated equity value of ...
Novo Nordisk announces agreement with the U.S. Administration to bring...
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost Obesity medicines coverage in U.S. Medicare Part D via a pilot programme, starting during 2026Introduction of lower prices for Novo Nordisk’s semaglutide medicines in U.S. Medicare Part D and Medicaid and in direct-to-patients cash channelNovo Nordisk currently expects an estimated negative low single-digit impact on global sales growth in 2026 Bagsværd, Denmark, 6 November 2025 – Today it was announced that Novo Nordisk has agreed with the U.S. Administration to lower drug price...
- Emira Sagaama
- Louis Boujard
- CFA
- Philippe Ourpatian
DHLN DHL GROUP
CON CONTINENTAL AKTIENGESELLSCHAFT
LRC LEGRAND
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
VIE VEOLIA ENVIRONNEMENT SA
EDEN EDENRED SA
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
BT.A BT GROUP PLC
MT ARCELORMITTAL SA
DGE DIAGEO PLC
RNO RENAULT SA
G1A GEA GROUP AG
KPN ROYAL KPN NV
GFC GECINA SA
DAI DAIMLER AG
EBS ERSTE GROUP BANK AG
ADEN ADECCO GROUP AG
SCMN SWISSCOM AG
MMK MAYR-MELNHOF KARTON AG
RHM RHEINMETALL AG
CDR CD PROJEKT S.A.
PKO PKO BANK POLSKI S.A.
TEP TELEPERFORMANCE SE
RF EURAZEO SA
ZAL ZALANDO SE
GEBN GEBERIT AG
ORSTED ORSTED
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
VOW3 VOLKSWAGEN AG PREF
HEN3 HENKEL AG & CO. KGAA PREF
CRG CRH PLC
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
RAA RATIONAL AG
EDW EDP RENOVAVEIS SA
TIT TELECOM ITALIA S.P.A.
COLO B COLOPLAST A/S CLASS B
INX IMCD N.V.
LDO LEONARDO SPA
AZN ASTRAZENECA PLC
NEXI NEXI S.P.A.
STLA STELLANTIS N.V.
VWS VESTAS WIND SYSTEMS
CTPNV CTP NV
NOVO B NOVO NORDISK A/S
ARM ARM HOLDINGS PLC
SYENS SYENSQO
UN0 UNIPER SE
AENA AENA S.M.E. SA
- Emira Sagaama
- Louis Boujard
- CFA
- Philippe Ourpatian
DHLN DHL GROUP
CON CONTINENTAL AKTIENGESELLSCHAFT
LRC LEGRAND
VIE VEOLIA ENVIRONNEMENT SA
EDEN EDENRED SA
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
BT.A BT GROUP PLC
MT ARCELORMITTAL SA
DGE DIAGEO PLC
G1A GEA GROUP AG
KPN ROYAL KPN NV
GFC GECINA SA
EBS ERSTE GROUP BANK AG
ADEN ADECCO GROUP AG
SCMN SWISSCOM AG
MMK MAYR-MELNHOF KARTON AG
RHM RHEINMETALL AG
CDR CD PROJEKT S.A.
PKO PKO BANK POLSKI S.A.
TEP TELEPERFORMANCE SE
RF EURAZEO SA
ZAL ZALANDO SE
GEBN GEBERIT AG
ORSTED ORSTED
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
HEN3 HENKEL AG & CO. KGAA PREF
CRG CRH PLC
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
RAA RATIONAL AG
EDW EDP RENOVAVEIS SA
TIT TELECOM ITALIA S.P.A.
COLO B COLOPLAST A/S CLASS B
INX IMCD N.V.
LDO LEONARDO SPA
AZN ASTRAZENECA PLC
NEXI NEXI S.P.A.
VWS VESTAS WIND SYSTEMS
CTPNV CTP NV
NOVO B NOVO NORDISK A/S
ARM ARM HOLDINGS PLC
SYENS SYENSQO
UN0 UNIPER SE
AENA AENA S.M.E. SA
- Martial Descoutures
- Martial Descoutures
- ABGSC Healthcare Research
- Morten Larsen
- Konrad Zomer
PUB PUBLICIS GROUPE SA
BVI BUREAU VERITAS SA
KPN ROYAL KPN NV
EN BOUYGUES SA
DEMANT DEMANT A/S
WKL WOLTERS KLUWER NV
ITRK INTERTEK GROUP PLC
VNA VONOVIA SE
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
NEM NEMETSCHEK SE
EVK EVONIK INDUSTRIES AG
RACE FERRARI NV
GRF.P GRIFOLS S.A. PREF CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
BIM BIOMERIEUX SA
SHL SIEMENS HEALTHINEERS AG
CCEP COCA-COLA EUROPEAN PARTNERS PLC
NEXI NEXI S.P.A.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SGSN SGS SA
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
- Martial Descoutures
- Konrad Zomer
PUB PUBLICIS GROUPE SA
BVI BUREAU VERITAS SA
EN BOUYGUES SA
DEMANT DEMANT A/S
WKL WOLTERS KLUWER NV
ITRK INTERTEK GROUP PLC
VNA VONOVIA SE
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
NEM NEMETSCHEK SE
EVK EVONIK INDUSTRIES AG
RACE FERRARI NV
GRF.P GRIFOLS S.A. PREF CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
BIM BIOMERIEUX SA
SHL SIEMENS HEALTHINEERS AG
CCEP COCA-COLA EUROPEAN PARTNERS PLC
NEXI NEXI S.P.A.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SGSN SGS SA
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.